Navigation Links
Shire Supports Rare Disease Day 2010
Date:3/1/2010

e's investigational enzyme replacement treatment for Type 1 Gaucher disease, by February 28.

"For many patients and their families, the journey to a diagnosis and subsequent treatment can be a long, complicated process," said Sylvie Gregoire, President of Shire Human Genetic Therapies (HGT). "Shire is committed to enabling people with life-altering conditions to lead better lives - and for us, this includes improving access to information as well as providing much-needed treatment for rare diseases."

    Shire's Global Rare Disease Day Initiatives include:

    - Extending BraveCommunity.com (http://www.bravecommunity.com), its
    online resource center that aims to connect patients with each other and
    to provide important information about rare diseases.

    - Supporting the Global Genes Project (http://www.globalgenesproject.org)
    , a grassroots effort to use denim jeans to raise global awareness of
    rare genetic disorders.

    - Supporting its non-profit partners as they visit Capitol Hill to
    advocate for patients with rare diseases in Washington, D.C.,

    - Co-sponsoring with FEDER (Spanish Federation for Rare Diseases) the
    Annual Running Race for Rare Disease Day in Madrid, Spain.

    - Organizing a special walk on February 28th in Brazil to raise awareness
    of rare diseases in the country. It is expected that more than 20 patient
    organizations and their members will participate.


    For the full press release please visit '/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of a groundbreaking new version of its flagship DNA design ... methodology breaks down complex DNA sequences into numerous genetic parts, which in turn ...
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics Holdings, ... announces that the Company,s lead antibody, HuMab 5B1, will ... separate presentations during the upcoming World Molecular Imaging Congress ... September 2-5, 2015. Researchers from the Department of Radiology ... results on the use of MabVax,s lead antibody as ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... SAN FRANCISCO, Calif. , Aug. 31, 2015 /PRNewswire/ ... the discovery and development of novel cancer immunotherapies, announced ... M.D., Ph.D., as Chief Executive Officer and William ... Wong and Ho join an experienced management team led ... Jordan Fridman , Ph.D., Chief Scientific Officer; ...
Breaking Biology Technology:GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... , , , 7.6.4 Long PCR , ... as desired with every temperature , command, enables a , ... , With Long PCR, this function can be used ... elongation. , , ...
... , , , , , ... set of conditions that can be applied to all PCR amplifications. For ... used, the annealing temperatures , of the PCRs can differ ... stringent annealing temperature is a prerequisite for reliable results , ...
... , , , , ... fragment using the PCR* are an everyday occurrence in the lab. For example, , ... which hinder, , or even prevent, further analyses (cycle ... of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... acetyl CoA carboxylase 2,or ACC2, appears to turn the ... in part why the animals can eat more and ... Medicine,researchers.,The report that appears online today in the Proceedings ... cells in these mice bred to lack ACC2," said ...
... University,of California, San Diego have invented a process ... of specialized cells being sought as possible,treatments for ... and Shu Chien, UCSD bioengineering professors, and Christopher,J. ... in a paper published in the February issue ...
... have discovered a way to overcome one of the ... kill normal cells in the,process of eradicating cancer cells.,In ... of the Proceedings of the,National Academy of Sciences (PNAS), ... into a specially designed,virus. The virus eradicated prostate cancer ...
Cached Biology News:Lack of enzyme turns fat cells into fat burners 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Columbia research lifts major hurdle to gene therapy for cancer 2